MedImmune has resolved the observations made by the FDA during an annual inspection of its influenza vaccine manufacturing facility in Speke, UK, according to the company. The company had received a Warning Letter from the FDA in May. The UK facility is the bulk manufacturing site for FluMist (Influenza Virus Vaccine Live, Intranasal). MedImmune will continue to work with the FDA on the implementation and ongoing execution of all quality and compliance concerns. MedImmune is currently worki...